1	The	DT	2	det
2	amount	NN	15	nsubjpass
3	of	IN	2	prep
4	blood	NN	3	pobj
5	surgical	JJ	6	amod
6	patients	NNS	8	nsubj
7	can	MD	8	aux
8	donate	VB	4	rcmod
9	and	CC	8	cc
10	store	VB	8	conj
11	before	IN	8	prep
12	surgery	NN	11	pobj
13	can	MD	15	aux
14	be	VB	15	auxpass
15	increased	VBN	0	root
16	by	IN	15	prep
17	the	DT	21	det
18	new	JJ	21	amod
19	genetically	RB	20	advmod
20	engineered	VBN	21	amod
21	drug	NN	16	pobj
22	,	,	21	punct
23	EPO	NNP	21	appos
24	.	.	15	punct

1	EPO	NNP	8	nsubj
2	,	,	1	punct
3	or	CC	1	cc
4	erythropoietin	NN	1	conj
5	,	,	1	punct
6	is	VBZ	8	cop
7	a	DT	8	det
8	protein	NN	0	root
9	the	DT	11	det
10	human	JJ	11	amod
11	body	NN	12	nsubj
12	makes	VBZ	8	rcmod
13	to	TO	14	aux
14	stimulate	VB	12	xcomp
15	the	DT	16	det
16	growth	NN	14	dobj
17	of	IN	16	prep
18	red	JJ	20	amod
19	blood	NN	20	nn
20	cells	NNS	17	pobj
21	.	.	8	punct

1	A	DT	4	det
2	genetically	RB	3	advmod
3	engineered	VBN	4	amod
4	version	NN	22	nsubjpass
5	of	IN	4	prep
6	the	DT	8	det
7	human	JJ	8	amod
8	protein	NN	5	pobj
9	developed	VBN	4	partmod
10	by	IN	9	prep
11	Amgen	NNP	12	nn
12	Corp.	NNP	10	pobj
13	of	IN	12	prep
14	Thousand	NNP	15	nn
15	Oaks	NNP	13	pobj
16	,	,	15	punct
17	Calif.	NNP	15	appos
18	,	,	15	punct
19	recently	RB	22	advmod
20	has	VBZ	22	aux
21	been	VBN	22	auxpass
22	marketed	VBN	0	root
23	by	IN	22	prep
24	the	DT	27	det
25	Ortho	NNP	26	nn
26	Pharmaceuticals	NNP	27	nn
27	division	NN	23	pobj
28	of	IN	27	prep
29	Johnson	NNP	28	pobj
30	&	CC	29	cc
31	Johnson	NNP	29	conj
32	.	.	22	punct

1	A	DT	3	det
2	competing	VBG	3	amod
3	version	NN	8	nsubjpass
4	of	IN	3	prep
5	EPO	NNP	4	pobj
6	is	VBZ	8	aux
7	being	VBG	8	auxpass
8	developed	VBN	0	root
9	by	IN	8	prep
10	Genetics	NNP	11	nn
11	Institute	NNP	12	nn
12	Inc.	NNP	9	pobj
13	in	IN	12	prep
14	Cambridge	NNP	13	pobj
15	,	,	14	punct
16	Mass	NNP	14	appos
17	.	.	8	punct

1	The	DT	2	det
2	drug	NN	5	nsubjpass
3	is	VBZ	5	aux
4	being	VBG	5	auxpass
5	used	VBN	0	root
6	primarily	RB	5	advmod
7	to	TO	8	aux
8	treat	VB	5	xcomp
9	anemias	NNS	8	dobj
10	.	.	5	punct

1	A	DT	3	det
2	new	JJ	3	amod
3	experiment	NN	16	nsubj
4	,	,	3	punct
5	reported	VBN	3	partmod
6	in	IN	5	prep
7	this	DT	8	det
8	week	NN	12	poss
9	's	POS	8	possessive
10	New	NNP	11	nn
11	England	NNP	12	nn
12	Journal	NNP	6	pobj
13	of	IN	12	prep
14	Medicine	NNP	13	pobj
15	,	,	3	punct
16	involved	VBD	0	root
17	giving	VBG	16	xcomp
18	injections	NNS	17	dobj
19	of	IN	18	prep
20	Amgen	NNP	22	poss
21	's	POS	20	possessive
22	EPO	NNP	19	pobj
23	to	TO	17	prep
24	23	CD	25	num
25	patients	NNS	23	pobj
26	who	WP	27	nsubj
27	wanted	VBD	25	rcmod
28	to	TO	29	aux
29	store	VB	27	xcomp
30	units	NNS	29	dobj
31	of	IN	30	prep
32	their	PRP$	34	poss
33	own	JJ	34	amod
34	blood	NN	31	pobj
35	.	.	16	punct

1	The	DT	2	det
2	patients	NNS	3	nsubj
3	began	VBD	0	root
4	receiving	VBG	3	xcomp
5	EPO	NNP	6	nn
6	injections	NNS	4	dobj
7	about	IN	8	quantmod
8	a	DT	9	num
9	month	NN	10	dep
10	before	IN	4	prep
11	their	PRP$	13	poss
12	scheduled	VBN	13	amod
13	surgery	NN	10	pobj
14	.	.	3	punct

1	They	PRP	3	nsubj
2	then	RB	3	advmod
3	began	VBD	0	root
4	donating	VBG	3	xcomp
5	blood	NN	4	dobj
6	twice	RB	8	advmod
7	a	DT	8	det
8	week	NN	4	tmod
9	,	,	4	punct
10	receiving	VBG	4	xcomp
11	an	DT	13	det
12	EPO	NNP	13	nn
13	injection	NN	10	dobj
14	each	DT	15	det
15	time	NN	10	tmod
16	.	.	3	punct

1	If	IN	3	mark
2	tests	NNS	3	nsubj
3	indicated	VBD	14	advcl
4	a	DT	6	det
5	low	JJ	6	amod
6	number	NN	3	dobj
7	of	IN	6	prep
8	red	JJ	9	amod
9	cells	NNS	7	pobj
10	,	,	14	punct
11	blood	NN	14	nsubjpass
12	was	VBD	14	auxpass
13	n't	RB	14	neg
14	taken	VBN	0	root
15	.	.	14	punct

1	The	DT	3	det
2	EPO-treated	JJ	3	amod
3	patients	NNS	4	nsubj
4	donated	VBD	0	root
5	an	DT	6	det
6	average	NN	4	dobj
7	of	IN	6	prep
8	5.4	CD	9	num
9	units	NNS	7	pobj
10	of	IN	9	prep
11	blood	NN	10	pobj
12	each	DT	6	npadvmod
13	compared	VBN	4	prep
14	with	IN	13	pcomp
15	only	RB	16	quantmod
16	4.1	CD	17	num
17	units	NNS	14	pobj
18	donated	VBN	17	partmod
19	by	IN	18	prep
20	a	DT	22	det
21	similar	JJ	22	amod
22	group	NN	19	pobj
23	of	IN	22	prep
24	surgical	JJ	25	amod
25	patients	NNS	23	pobj
26	who	WP	27	nsubj
27	received	VBD	25	rcmod
28	a	DT	30	det
29	placebo	NN	30	nn
30	injection	NN	27	dobj
31	.	.	4	punct

1	The	DT	2	det
2	volume	NN	11	nsubj
3	of	IN	2	prep
4	red	JJ	5	amod
5	cells	NNS	3	pobj
6	donated	VBN	5	partmod
7	by	IN	6	prep
8	the	DT	10	det
9	EPO-treated	JJ	10	amod
10	patients	NNS	7	pobj
11	was	VBD	29	ccomp
12	41	CD	13	num
13	%	NN	14	npadvmod
14	higher	JJR	11	advmod
15	per	IN	11	prep
16	donor	NN	15	pobj
17	,	,	29	punct
18	the	DT	20	det
19	research	NN	20	nn
20	team	NN	29	nsubj
21	representing	VBG	20	partmod
22	a	DT	23	det
23	number	NN	21	dobj
24	of	IN	23	prep
25	hospitals	NNS	24	pobj
26	and	CC	25	cc
27	blood	NN	28	nn
28	banks	NNS	25	conj
29	reported	VBD	0	root
30	.	.	29	punct


